FDA recommends science-based approach
With so many questions around the safety and quality of CBD products, the FDA looks at policy to ensure safe standards are maintained for the production of CBD.
Education
Informed decisions.
Safer choices.
Understanding CBD is key to knowing what it can do. CBMD™ gathers resources and research to help physicians and consumers understand what’s in the products they use.
Year CBD was first isolated and identified by Harvard chemist Roger Adams.
Percent of US doctors that have discussed CBD/cannabis with their patients.
Amount of US doctors who feel they know enough about CBD to advise their patients on product selection or utility.
Our partnership
A common purpose.
CBMD™ operates in association with Cannabiomed™, a consortium of medical professionals, researchers, scientists, and pharmacists working to bring a medical perspective to the CBD industry.
Cannabiomed™ seeks to equip healthcare practitioners with resources that enable them to be informed, effective advisors for patients wanting to integrate CBD into their wellness routines.
Cannabidiol (CBD) is one of 113 biologic compounds—called cannabinoids—found within the trichomes of the cannabis/hemp plant. Two of the most well-known of these compounds are CBD and THC. While both are naturally occurring, CBD is distinct from THC, in that CBD does not produce the psychoactive effect (or high) that THC does.
All cannabinoid molecules, like those found in CBD, act on the receptors in the body’s endocannabinoid system (ECS). Active in the body whether or not a person uses CBD or THC products, the ECS plays a role in sleep, appetite, mood, memory, and immune processes.
All CBMD products are formulated with broad-spectrum CBD, which has been purified to substantially reduce the THC content and profile.
Today, one can find CBD labeled full-spectrum, broad-spectrum, and pure isolate. Full-spectrum products contain precisely that: the full range of both cannabinoids and terpenes present in the plant. (Terpenes are the chemicals responsible for the smell and taste associated with cannabis). Full-spectrum products are notable in that they are inclusive of THC.
However, by definition, CBD cannot contain more than 0.3% of THC. On the other hand, broad-spectrum products are refined so as to remove much more of the THC content and profile. CBD isolate is created by extracting CBD and then removing all other cannabinoids and terpenes, isolating only the CBD molecules.
Determining the appropriate CBD dose is dependent upon a number of factors, including the delivery technology, concentration, and product type. There are also other factors to consider, like a person’s unique biological makeup, and medicines an individual might be taking, Additionally, CBD isolate will exert a different kind of dose response than broad-spectrum and full-spectrum products. Because of this variability, we recommend that individuals consult a doctor, and also begin with a low dosage and build from there.
The term bioavailability refers to the percentage or fraction of a given dose that is absorbed into the bloodstream, and therefore made available for use by the body. Bioavailability is based on a variety of factors, including product composition and method of delivery. In several of our CBD formulations, we incorporate ingredients that display increased and prolonged bioavailability.
All cannabinoid molecules, like those found in CBD, act on the receptors in the body’s endocannabinoid system (ECS). Active in the body whether or not a person uses CBD or THC products, the ECS plays a role in sleep, appetite, mood, memory, and immune processes.
There are two main kinds of receptors: CB1 receptors, which are mainly concentrated in the brain, and CB2 receptors, located throughout the body and largely connected with immune system function.
The human body also produces its own endocannabinoids, a fact that is part of an interesting story of the endocannabinoid system’s scientific provenance—starting in the early 19th century and leading to the recent mapping of the endocannabinoid receptors’ genetic group.
Featured publication
News and research
Created by Americans for Safe Access (ASA),The Patient’s Guide to CBD is an informative resource for patients, healthcare providers, consumers, and others seeking information on the topic of cannabidiol (CBD).
Open PDF